Taiyen Biotech Co. Ltd.

As of June 30, 2026, Taiyen Biotech Co. Ltd. carries a market capitalization of 6.38B, placing it among publicly traded companies globally. Its enterprise value stands at 4.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Taiyen Biotech Co. Ltd. has 200.00M shares outstanding.

As of June 30, 2026, Taiyen Biotech Co. Ltd. trades at a trailing price-to-earnings ratio of 16.38. The price-to-sales ratio is 2.00, and the price-to-book ratio stands at 0.95.

As of June 30, 2026, Taiyen Biotech Co. Ltd. trades at an EV/EBITDA multiple of 6.78 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.87 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Taiyen Biotech Co. Ltd. trades at an EV/FCF ratio of 18.80, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 4.64B versus a market cap of 6.38B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Taiyen Biotech Co. Ltd. maintains a current ratio of 2.48, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.40, indicating elevated leverage, while an interest coverage ratio of 257.22 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Taiyen Biotech Co. Ltd. posted a return on equity (ROE) of 5.87, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.00 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.65, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.69, useful for judging operating efficiency across full business cycles. The company generates approximately 6.66M in revenue per employee across its workforce of 479.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.28 indicates how many times Taiyen Biotech Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Taiyen Biotech Co. Ltd. recorded 90.75M in income tax expense. That works out to an effective tax rate of 18.89, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 480.27M, leaving 389.53M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Taiyen Biotech Co. Ltd.'s stock has declined approximately 5.78% over the past 52 weeks. The 50-day moving average sits at 30.66, while the 200-day moving average is 31.46.

Over the twelve months ended June 30, 2026, Taiyen Biotech Co. Ltd. generated 3.19B in revenue and converted that into 389.53M in net income, yielding earnings per share of 1.94. EBITDA reached 684.73M, while operating income came in at 395.58M.

As of June 30, 2026, Taiyen Biotech Co. Ltd. holds 1.97B in cash and equivalents against 228.22M in total debt, resulting in a net debt position of -1.37B. Total book value stands at 6.71B, with working capital of 1.72B providing operational flexibility.

Taiyen Biotech Co. Ltd. produced 553.60M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -308.84M in capital expenditures, free cash flow totaled 244.76M - equivalent to 1.22 per share.

Over the twelve months ended June 30, 2026, Taiyen Biotech Co. Ltd. posted a gross margin of 39.46, reflecting its pricing power and cost economics. The operating margin of 12.40 and net profit margin of 12.21 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Taiyen Biotech Co. Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.83, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.13, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Taiyen Biotech Co. Ltd. shareholders.

Taiyen Biotech Co. Ltd.'s most recent stock split took place on December 30, 2013 with a 146:105 split ratio.

As of June 30, 2026, Taiyen Biotech Co. Ltd. has an Altman Z-Score of 3.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.